GeneHealth - Your precision medicine

Nemaline Myopathy

Disease Details

Family Health Simplified

Buy Membership

Description: Nemaline myopathy is a rare genetic disorder characterized by muscle weakness, typically affecting skeletal muscles, with the presence of rod-like structures (nemaline bodies) in muscle cells.
Type: Nemaline myopathy is primarily inherited in an autosomal recessive or autosomal dominant manner, depending on the specific gene mutation involved.
Signs And Symptoms: Signs vary from person to person. Young children and babies lack movement and have a difficult time eating and breathing. For young children not diagnosed immediately at birth, these are usually the first visible symptoms. One sign is a swollen face in disproportional areas. Other examples in newborns include swaying and a difficulty in moving. Other symptoms include feeble muscles in the neck and upper rib cage area. In adults, the most common symptom is respiratory problems. Other symptoms in adults could range from mild to severe speech impediments. It is common to be diagnosed with scoliosis in relations to nemaline myopathy.
As babies that have NM develop and become of age when they should start walking, many take longer than average due to the lack of muscle, or just muscle fatigue.Since facial muscles are involved in NM takeover, elongated faces and a lower mandible are often observed in people with NM. People affected by NM usually will begin to feel muscle exhaustion between ages 20–50. NM is usually not progressive. Gastroesophageal reflux, although not common, is associated with NM. Heart abnormalities can occur as a result of NM, but the likelihood of that happening are not high.
Prognosis: Nemaline myopathy is a congenital neuromuscular disorder characterized by muscle weakness and the presence of rod-like structures (nemaline bodies) in muscle fibers. The prognosis for individuals with nemaline myopathy can vary widely based on the severity of the condition, which ranges from mild to severe forms.

In mild cases, individuals may experience slight muscle weakness and have a near-normal life expectancy, with some physical limitations becoming more apparent with age. Moderate cases may result in significant muscle weakness, respiratory complications, and mobility issues, potentially requiring long-term medical and supportive care. Severe cases can present with profound muscle weakness from birth, significant respiratory difficulties, and feeding problems, often leading to a more limited lifespan.

Overall, the management of nemaline myopathy involves supportive therapies such as respiratory support, physical therapy, and nutritional management to improve quality of life and outcomes.
Onset: Nemaline myopathy typically presents with symptoms at birth or in early childhood, although later onset during adulthood is also possible. The severity of the disease can vary widely.
Prevalence: Nemaline myopathy is a rare neuromuscular disorder, with an estimated prevalence of approximately 1 in 50,000 live births.
Epidemiology: Nemaline myopathy is a rare congenital neuromuscular disorder. Its incidence is estimated to be around 1 in 50,000 live births. The condition affects individuals worldwide, with no significant predilection for any specific ethnic or racial group. Nemaline myopathy is typically inherited in an autosomal dominant or recessive manner, with mutations in at least 13 different genes identified as contributing factors.
Intractability: Yes, nemaline myopathy is generally considered intractable, meaning it currently has no cure. The condition involves muscle weakness due to abnormalities in muscle fibers, and treatment primarily focuses on managing symptoms and improving quality of life through physical therapy and supportive care.
Disease Severity: The severity of nemaline myopathy can vary widely from person to person. It ranges from mild cases with minor muscle weakness to severe cases with significant muscle weakness, respiratory issues, and even early infant death. The extent and progression of the disease depend on the specific genetic mutations involved.
Healthcare Professionals: Disease Ontology ID - DOID:3191
Pathophysiology: Nemaline myopathy is a genetic disorder that affects the skeletal muscles. It is characterized by the presence of rod-like structures called nemaline bodies in the muscle fibers. These abnormal structures interfere with the function of muscle cells.

### Pathophysiology:

1. **Genetic Mutations**: Nemaline myopathy is predominantly caused by mutations in several genes, such as ACTA1, NEB, TPM2, TPM3, TNNT1, and CFL2. These genes are responsible for encoding proteins that are crucial for muscle contraction and structure.

2. **Protein Dysfunction**: The mutations lead to the production of abnormal proteins or insufficient amounts of normal proteins, which disrupt the assembly and function of the sarcomere, the basic unit of muscle fiber.

3. **Formation of Nemaline Bodies**: The defective proteins aggregate to form nemaline bodies, which appear as rod-like structures under a microscope. These bodies are composed mainly of Z-disc material from the sarcomeres and actin filaments.

4. **Muscle Weakness**: The presence of nemaline bodies interferes with normal muscle contraction and leads to muscle weakness. The degree of weakness can vary widely, from mild to severe, depending on the specific mutation and the amount of functional protein.

5. **Muscle Fiber Deformities**: Nemaline myopathy also results in other muscle fiber anomalies, including fiber size variation and an increase in central nuclei.

Overall, nemaline myopathy disrupts the normal structure and function of muscle fibers, leading to the clinical manifestations of muscle weakness and related complications.
Carrier Status: Nemaline myopathy is typically an autosomal recessive disorder. In the autosomal recessive form, a carrier (heterozygous) has one copy of the mutated gene but usually does not show symptoms of the disease. If both parents are carriers, there is a 25% chance with each pregnancy that their child will have the disease, a 50% chance the child will be a carrier, and a 25% chance the child will neither be affected nor a carrier.
Mechanism: Muscle cells contract in complex mechanical and chemical processes. If any part of the process or structure is disrupted, dysfunction will likely result, as in the case of those with genetic variations. In those with nemaline myopathy, muscle contraction is adversely affected. At the electron microscopic level, rod-shaped components can often be seen in some of the muscle cells, and when seen, are diagnostic for the condition called nemaline rod myopathy. The presence of these rods is not itself causing muscle weakness; rather they appear as a result of something going wrong within the muscle fiber. There is no connection between the number of rods found in the muscle cells and the amount of weakness a person has. All of the different gene mutations leading to the condition called nemaline myopathy that have been found so far are in genes that encode different components of the sarcomere. In normal muscle cells, the various parts of the muscle fibers that make up the sarcomere are distributed evenly in a pattern for effective muscle contraction. Evidence suggests that some kinds of NM affect the arrangement of these muscle fibers, causing the muscles to be unable to contract as efficiently or effectively.
Nemaline myopathy is usually genetic and shows traits in the affected individual from birth or an early age. However, there are some cases of symptoms of nemaline myopathy not showing up until adulthood. These cases are usually not genetic. Of the genes that have been linked to nemaline myopathy, most are also involved in encoding proteins in the sarcomeres in the muscle cells. Respiratory muscles are often more affected than other skeletal muscle groups. Cardiac muscle is usually not affected in nemaline myopathy; however, in cases where it does, patients often present with dilated cardiomyopathy. The ocular muscles are usually spared.The different genes whose mutations lead to the different kinds of nemaline myopathies affect the cells and the person's body differently. The first kind of nemaline myopathy identified is due to the Slow α-Tropomyosin Gene TPM3 and varies from case to case with its severity. In this kind of nemaline myopathy, affected people are weaker and more affected in their lower limbs than their upper limbs.As stated above, the most common genetic form of NM is caused by a mutation in the nebulin gene, called Nebulin, and has a range of severity levels. All published cases up to this point where NM is thought to be caused by a mutation in the NEB gene have been autosomal recessive and are the most common cause of nemaline myopathy. Patients with this kind of NM are more affected in the muscles in their head, rather than their proximal muscles at the core of their body. Consequently, patients with this genetic mutation often cannot lift their heads and speak with a nasal voice. There have been cases that suggest this kind of NM may lead to patients having higher intellect.A third kind of nemaline myopathy in the Skeletal Muscle α-Actin Gene ACTA1 is due to a recessive null mutation. These patients do not always show the typical nemaline bodies in their muscle cells. The only abnormality they show is an abnormal distribution of muscle fibers.
There are several other identified kinds of mutations that lead to Nemaline Myopathies. One affects slow skeletal muscles, one leads to the formation of both nemaline bodies and other abnormal, core-like, structures forming in the patient's muscles.
Treatment: At present, Nemaline myopathy does not have a cure. Nemaline myopathy is a very rare disease that only affects 1 out of 50,000 on average, although recent studies show that this number is even smaller. There are a number of treatments to minimize the symptoms of the disease. The treatments and procedures to help patients with nemaline myopathy vary depending on the severity of the disease. A possible accommodation could be the use of a stabilizer, such as a brace. Other means include moderate stretching and moderate exercise to help target muscles maintain maximum health.
As people with NM grow and develop throughout their lives, it is important for them to see a variety of health professionals regularly, including a neurologist, physical therapist, and others, such as speech therapists and psychologists, to help both the patient and family adjust to everyday life.
Compassionate Use Treatment: Nemaline myopathy is a rare neuromuscular disorder characterized by muscle weakness and the presence of rod-like structures (nemaline bodies) in muscle cells. Currently, there is no curative treatment for nemaline myopathy, and management typically focuses on supportive care.

For compassionate use and experimental treatments:

1. **Gene Therapy**: Researchers are exploring gene therapy approaches to deliver corrected genetic material to patients' muscle cells. This area is still in investigational stages.

2. **Nusinersen (Spinraza)**: Originally approved for spinal muscular atrophy, nusinersen has shown potential in early studies for improving muscle function in certain neuromuscular disorders and may be considered off-label for nemaline myopathy.

3. **L-citrulline**: This amino acid has been used experimentally to improve muscle function and reduce fatigue in some patients with different forms of myopathies, including nemaline myopathy.

4. **ATB200/AT2221**: While primarily designed for Pompe disease, these enzyme replacement therapies are being explored in clinical trials for their potential application in other muscle disorders.

Any use of these treatments should be discussed with a healthcare provider specializing in neuromuscular disorders to evaluate the potential benefits and risks.
Lifestyle Recommendations: Nemaline myopathy is a rare congenital muscle disorder characterized by muscle weakness. Here are some lifestyle recommendations for managing the condition:

1. **Physical Therapy:** Regular sessions with a physical therapist can help maintain muscle strength and flexibility. Tailored exercise programs can maximize functional abilities.

2. **Respiratory Care:** Breathing exercises and, in severe cases, ventilatory support might be necessary to maintain respiratory function.

3. **Nutritional Support:** A balanced diet is crucial for overall health. In cases of swallowing difficulties, working with a nutritionist can ensure adequate caloric and nutrient intake, possibly including the use of feeding tubes.

4. **Orthopedic Interventions:** Braces or other orthopedic devices may help support mobility and posture, improving comfort and function.

5. **Regular Monitoring:** Routine check-ups with healthcare providers to monitor muscle strength, respiratory function, and nutritional status are important for timely interventions.

6. **Adaptive Equipment:** Using wheelchairs or other assistive devices can promote independence and mobility, enhancing the quality of life.

7. **Educational Support:** For children, individualized education plans (IEPs) and occupational therapy can accommodate their learning needs.

8. **Support Groups:** Connecting with others who have nemaline myopathy through support networks can provide emotional support and practical advice.

It's important to work closely with a multidisciplinary healthcare team to tailor these recommendations to the individual’s specific needs and circumstances.
Medication: Currently, there is no cure for nemaline myopathy, and treatment primarily focuses on supportive care. However, there isn't a standardized medication specifically approved for nemaline myopathy. Management strategies often include physical therapy, respiratory support, and addressing nutritional needs to improve the quality of life for patients. Researchers are continually exploring potential treatments and medications in clinical trials, but none have yet been specifically approved for the condition.
Repurposable Drugs: Nemaline myopathy is a rare neuromuscular disorder characterized by muscle weakness and the presence of rod-like structures in muscle cells. As of now, treatment primarily focuses on managing symptoms and supportive care. There are no well-established repurposable drugs specifically for nemaline myopathy, and research is ongoing to find effective therapies.
Metabolites: Nemaline myopathy is a rare congenital myopathy characterized by muscle weakness and the presence of rod-like structures called nemaline bodies in muscle cells. Information specifically about "metabolites, nan" (assuming "nan" refers to 'not available or not applicable') is generally limited, as this condition is primarily diagnosed through genetic testing and muscle biopsy rather than metabolite analysis. However, some relevant aspects include:

1. **Creatine Kinase (CK) Levels**: Typically, CK levels might be normal or slightly elevated in nemaline myopathy, which can be a useful marker in evaluating muscle diseases.
2. **Lactic Acid**: Elevated lactic acid levels may sometimes be observed as a secondary effect due to muscle weakness and decreased exercise capacity.
3. **Metabolic Considerations**: Routine metabolic panels usually do not reveal specific abnormalities directly associated with nemaline myopathy.

Since research on this disease is ongoing, the role of specific metabolites may evolve with future studies.
Nutraceuticals: There is limited evidence directly supporting the use of nutraceuticals for the treatment or management of nemaline myopathy. Nemaline myopathy is a congenital, hereditary muscle disorder characterized by weakness, and management typically involves supportive care and physical therapy. Nutraceuticals such as certain vitamins, minerals, and amino acids might be considered to support overall health, but their efficacy specifically for nemaline myopathy has not been well-established.

If you are considering nutraceuticals as part of a management plan for nemaline myopathy, it is essential to consult with a healthcare provider to tailor an appropriate approach based on individual health needs and the current evidence.
Peptides: Nemaline myopathy is a neuromuscular disorder characterized by muscle weakness and the presence of rod-like structures called nemaline bodies in muscle fibers. Peptides can be relevant in understanding this condition as mutations in genes encoding muscle proteins (such as actin and nebulin) play a role in its pathology. These proteins are made up of peptides, and mutations can lead to improper peptide sequences, affecting muscle function. Research into therapeutic peptides, which can mimic or influence the function of these muscle proteins, is ongoing. Nanotechnology, or nanomedicine, may potentially offer new diagnostic and therapeutic approaches, such as targeted drug delivery systems or molecular imaging techniques, to better understand and treat nemaline myopathy.